The Course of Adverse Events in Venlafaxine XR Treatment in Generalized Anxiety Disorder

被引:3
|
作者
Rickels, Karl [1 ]
Gallop, Robert [2 ]
Cleary, Sean [3 ]
机构
[1] Univ Penn, Dept Psychiat, 3535 Market St,Suite 670, Philadelphia, PA 19146 USA
[2] West Chester Univ, Dept Math, Appl Stat Program, W Chester, PA USA
[3] Harcum Coll, Dept Gen Studies, Media, PA USA
关键词
adverse events; generalized anxiety disorder; attrition; TOLERABILITY;
D O I
10.1097/JCP.0000000000001027
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
Purpose The time course of adverse events is an important factor for patient management. Clinicians are better able to prepare patients for specific adverse events, which leads to better treatment adherence. Methods Adverse events were followed longitudinally for 6 months during the open-label phase of a relapse prevention trial with 264 patients with generalized anxiety disorder. Adverse events were assessed at each treatment visit using a 21-item checklist. Logistic regression modeling, continuation ratio modeling, and hierarchical linear modeling were used to determine whether adverse events led to early attrition and whether adverse events decreased in enrolled patients over time. Findings Adverse events were found to have decreased highly significantly during treatment. A highly significant race effect was found in that whites had a significantly higher adverse event rate than did nonwhites. Early attrition rates were predicted by presence of nausea and fatigue, late attrition by dizziness, nervousness, and sexual dysfunction.
引用
收藏
页码:258 / 260
页数:3
相关论文
共 50 条
  • [1] Venlafaxine extended release (XR) in the treatment of generalized anxiety disorder
    Sheehan, DV
    [J]. JOURNAL OF CLINICAL PSYCHIATRY, 1999, 60 : 23 - 28
  • [2] Long-term treatment of generalized social anxiety disorder with venlafaxine XR
    Hackett, D
    Stein, MB
    Mangano, R
    Pollack, M
    [J]. EUROPEAN NEUROPSYCHOPHARMACOLOGY, 2003, 13 : S380 - S381
  • [3] Characterization of the longitudinal course of improvement in generalized anxiety disorder during long-term treatment with venlafaxine XR
    Montgomery, SA
    Sheehan, DV
    Meoni, P
    Haudiquet, V
    Hackett, D
    [J]. JOURNAL OF PSYCHIATRIC RESEARCH, 2002, 36 (04) : 209 - 217
  • [4] Efficacy, safety, and tolerability of venlafaxine XR in generalized anxiety disorder
    Kelsey, JE
    [J]. DEPRESSION AND ANXIETY, 2000, 12 : 81 - 84
  • [5] Improvement in functionality with treatment of generalized social anxiety disorder: Venlafaxine XR vs placebo
    Mallick, R
    Mangano, R
    Shrivastava, RK
    [J]. EUROPEAN NEUROPSYCHOPHARMACOLOGY, 2002, 12 : S356 - S357
  • [6] Pattern of symptom improvement following treatment with venlafaxine XR in patients with generalized anxiety disorder
    Meoni, P
    Salinas, E
    Brault, Y
    Hackett, D
    [J]. JOURNAL OF CLINICAL PSYCHIATRY, 2001, 62 (11) : 888 - 893
  • [7] Venlafaxine XR versus fluoxetine in the treatment of major depressive disorder and generalized anxiety disorder dual diagnosis
    Vasile, D.
    Vasiliu, O.
    Ivanov, P.
    Ojog, D.
    Sarmache, M.
    Vasile, M.
    [J]. EUROPEAN PSYCHIATRY, 2007, 22 : S247 - S247
  • [8] Venlafaxine XR in the treatment of anxiety
    Hackett, D
    [J]. ACTA PSYCHIATRICA SCANDINAVICA, 2000, 102 : 30 - 35
  • [9] Genome-wide association study of treatment response to venlafaxine XR in generalized anxiety disorder
    Jung, Jeesun
    Tawa, Elisabeth A.
    Muench, Christine
    Rosen, Allison D.
    Rickels, Karl
    Lohoff, Falk W.
    [J]. PSYCHIATRY RESEARCH, 2017, 254 : 8 - 11
  • [10] Genome-Wide Association Study of Treatment Response to Venlafaxine XR in Generalized Anxiety Disorder
    Tawa, Elisabeth A.
    Jung, Jeesun
    Rosen, Allison
    Rickels, Karl
    Lohoff, Falk W.
    [J]. BIOLOGICAL PSYCHIATRY, 2016, 79 (09) : 69S - 69S